Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Brief Summary: The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine, Procedure: Radiotherapy | Intervention Type: BIOLOGICAL; Name: Immunotherapeutic GSK1572932A; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Cisplatin (CDDP); Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: PROCEDURE; Name: Radiotherapy; Assigned to Arm(s): Cohort 4
C: Arm Label: GSK1572932 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Control | Intervention Type: BIOLOGICAL; Name: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Assigned to Arm(s): GSK1572932 Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): Placebo Group
D: Arm Label: Melanoma - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: RCC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: mCRPC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: NSCLC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: CRC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): Melanoma - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): RCC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): mCRPC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): NSCLC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): CRC - BMS-936558 (MDX-1106)

Answer: C